# Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

> **NCT04823091** · PHASE1 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 24 (estimated)

## Conditions studied

- T-Cell Lymphocytic Leukemia
- T-Cell Chronic Lymphocytic Leukemia
- T Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Fludarabine + Cyclophosphamide + CAR7-T Cells

## Key facts

- **NCT ID:** NCT04823091
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-15
- **Primary completion:** 2023-04-07
- **Final completion:** 2024-04-07
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823091, "Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04823091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*